Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 29;23(23):14953.
doi: 10.3390/ijms232314953.

Intraarticular Injections of Mesenchymal Stem Cells in Knee Osteoarthritis: A Review of Their Current Molecular Mechanisms of Action and Their Efficacy

Emérito Carlos Rodríguez-Merchán  1   2
Affiliations
Review

Intraarticular Injections of Mesenchymal Stem Cells in Knee Osteoarthritis: A Review of Their Current Molecular Mechanisms of Action and Their Efficacy

Emérito Carlos Rodríguez-Merchán. Int J Mol Sci. .

Abstract

More than 10% of the world's population suffers from osteoarthritis (OA) of the knee, with a lifetime risk of 45%. Current treatments for knee OA pain are as follows: weight control; oral pharmacological treatment (non-steroidal anti-inflammatory drugs, paracetamol, opioids); mechanical aids (crutches, walkers, braces, orthotics); therapeutic physical exercise; and intraarticular injections of corticosteroids, hyaluronic acid, and platelet-rich plasma (PRP). The problem is that such treatments usually relieve joint pain for only a short period of time. With respect to intraarticular injections, corticosteroids relieve pain for several weeks, while hyaluronic acid and PRP relieve pain for several months. When the above treatments fail to control knee pain, total knee arthroplasty (TKA) is usually indicated; however, although a very effective surgical technique, it can be associated with medical and postoperative (surgery-related) complications. Therefore, it seems essential to look for safe and effective alternative treatments to TKA. Recently, there has been much research on intraarticular injections of mesenchymal stem cells (MSCs) for the management of OA of the knee joint. This article reviews the latest information on the molecular mechanisms of action of MSCs and their potential therapeutic benefit in clinical practice in patients with painful knee OA. Although most recent publications claim that intraarticular injections of MSCs relieve joint pain in the short term, their efficacy remains controversial given that the existing scientific information on MSCs is indecisive. Before recommending intraarticular MSCs injections routinely in patients with painful knee OA, more studies comparing MSCs with placebo are needed. Furthermore, a standard protocol for intraarticular injections of MSCs in knee OA is needed.

Keywords: MSCs; efficacy; knee; mechanisms of action; osteoarthritis.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Figures

Figure 1
Figure 1
This image shows that the function of mesenchymal stem cells plays significant roles in the repair and regeneration process.
Figure 2
Figure 2
Mesenchymal stem cells (MSCs): cellular effect of their action. OA = osteoarthritis; ERK = extracellular signal-regulated protein kinase; VCL = vinculin; lncRNA = long non-coding RNA.
Figure 3
Figure 3
Pros and cons of allogenic and autologous mesecnchymal stem cells (MSCs).
See this image and copyright information in PMC

References

    1. Rodriguez-Merchan E.C. Intra-articular injections of hyaluronic acid and other drugs in the knee joint. HSS J. 2013;9:180–182. doi: 10.1007/s11420-012-9320-x. - DOI - PMC - PubMed
    1. Li W., Pan J., Lu Z., Zhu H., Guo J., Xie D. The application of platelet-rich plasma in the treatment of knee osteoarthritis: A literature review. J. Orthop. Sci. 2022;27:420–428. doi: 10.1016/j.jos.2021.01.006. - DOI - PubMed
    1. Losina E., Weinstein A.M., Reichmann W.M., Burbine S.A., Solomon D.H., Daigle M.E., Rome B.N., Chen S.P., Hunter D.J., Suter E.G., et al. Lifetime risk and age at diagnosis of symptomatic knee osteoarthritis in the US. Arthritis Care Res. 2013;65:703–711. doi: 10.1002/acr.21898. - DOI - PMC - PubMed
    1. Bannuru R.R., Osani M.C., Vaysbrot E.E., Arden N.K., Bennell K., Bierma-Zeinstra S.M.A., Kraus V.B., Lohmander L.S., Abbott J.H., Bhandari M., et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthr. Cartil. 2019;27:1578–1589. doi: 10.1016/j.joca.2019.06.011. - DOI - PubMed
    1. Bruyère O., Honvo G., Veronese N., Arden N.K., Branco J., Curtis E.M., Al-Daghri N.M., Herrero-Beaumont G., Martel-Pelletier J., Pelletier J.P., et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) Semin. Arthritis Rheum. 2019;49:337–350. doi: 10.1016/j.semarthrit.2019.04.008. - DOI - PubMed